drugset / Trial / NCT03066739

Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

NCT03066739

Phase 2 Terminated 8 enrolled University of California, Irvine
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery. There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone). The hypothesis of the study is that occurrence of remifentanil-induced hyperalgesia (low score in mechanical pain threshold) in the HN group will be lower than in the HI group.

Timeline

Start
2023-02-25
Primary completion
2024-12-10
Completion
2025-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxone Small molecule 0.004 unknown
Comparator Remifentanil Small molecule 0.1 unknown
Comparator Remifentanil Small molecule 0.4 mg
Comparator Remifentanil Small molecule 0.4 unknown

Indications

No indication recorded.